πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12203098

Cells having solid tumor targeting backbone and use thereof

Fate Therapeutics, Inc. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12195724

Methods of producing T cell populations enriched for stable regulatory T-cells

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12188005

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187777

Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187780

Car t-cells comprising inactivated CBL and CBL-B genes

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12180509

Methods for reprograming non-pluripotent cells into pluripotent stem cells

BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12171786

Use of mesenchymal stem cells for the treatment of inflammation

The Regents of the University of California Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12171818

Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173324

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173317

Use of histone modifiers to reprogram effector T cells

The Board of Regents of the University of Texas System Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173274

Enhanced immune effector cells and use thereof

Fate Therapeutics, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12171785

Pluripotent cells derived from bone marrow and methods for isolation

Regents of the University of Minnesota Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12170134

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12163153

Methods of manufacturing allogeneic CAR T cells

Allogene Therapeutics, Inc. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12161674

CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12157778

Peptides for activation of cell signaling in osteoprogenitor cells

The Regents of the University of California Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12159700

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12139522

T-cells comprising two different chimeric antigen receptors and uses thereof

THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109236

Manipulating ARID5B expression in immune cells to promote metabolism, survival, and functi

Regents of the University of Minnesota Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12109239

Methods for production of human hemogenic endothelial cells from pluripotent stem cells an

Astellas Institute for Regenerative Medicine Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104172

Processes for generating TIL products enriched for tumor antigen-specific t-cells

Iovance Biotherapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12098182

Polypeptides, cells, and methods involving engineered CD16

Regents of the University of Minnesota Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097223

Mesenchymal stromal cells and uses related thereto

Astellas Institute for Regenerative Medicine Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12083191

Composition and methods for imaging cells

Northwestern University Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted